ATB107 is a potent and novel inhibitor of indole-3-glycerol phosphate synthase (IGPS, KD: 3 μM).

IGPS:(kd)3 μM

ATB107 exhibits potent antibacterial activity against M. tuberculosis H37Ra and H37Rv strains with a minimum inhibitory concentration (MIC) of 0.1 μg/mL. Additionally, it effectively inhibits 100% of 50 fully susceptible clinical isolates at a concentration of 1 μg/mL, and 82% of these isolates at a concentration of 0.1 μg/mL. Among multidrug-resistant TB (MDR-TB) isolates, 83.8% are susceptible to ATB107 at 1 μg/mL, with a lower susceptibility rate of 31.3% observed at 0.1 μg/mL. Furthermore, the efficacy of ATB107 is concentration-dependent, correlating directly with its binding ability. Specifically, at a concentration of 200 μg/mL, ATB107 impedes cell proliferation, resulting in a survival rate of approximately 60%. Conversely, a lower concentration of 50 μg/mL ensures a cell survival rate exceeding 80%, highlighting its potency and concentration-dependent effects.